Category Archives: Cardiac Regeneration

References Allen RE, Sheehan SM, Taylor RG, Kendall TL and Rice GM (1995) Hepatocyte growth factor activates quiescent skeletal muscle satellite cells in vitro. Journal of Cellular Physiology 165: 307312. Ausoni S and Sartore S (2009) From fish to amphibians to mammals: in search of novel strategies to optimize cardiac regeneration. Journal of Cell Biology 84: 357364. Brockes JP and Kumar A (2008) Comparative aspects of animal regeneration. Annual Review of Cell and Developmental Biology 24: 525549. Carlson BM (1973) The regeneration of skeletal muscle: a review. American Journal of Anatomy 137: 119150. Carlson BM (1979) Relationship between the tissue and epimorphic regeneration of skeletal muscle. In: Mauro A (ed.) Muscle Regeneration, pp. 5772. New York: Raven Press. Carlson BM (2003) Muscle regeneration in amphibians and mammals: passing the torch. Developmental Dynamics 226: 167181. Carlson BM (2008) Muscle regeneration in animal models. In: Schiaffino S and Partridge TA (eds) Skeletal Muscle Repair and Regeneration, pp. 163179. The Netherlands: Springer. Corselli M, Chen CW, Crisan M, Lazzari L and Pault B (2010) Perivascular ancestors of adult multipotent stem cells. Arteriosclerosis, Thrombosis, and Vascular Biology 30: 11041109. Dhawan J and Rando TA (2005) Stem cells in postnatal myogenesis: molecular mechanisms of satellite … Continue reading →

Researchers in the Laboratory for Cardiac Regeneration in the Michael E. DeBakey Department of Surgery at Baylor College of Medicine arestudying whether cellular reprogramming can be applied to improve cardiac infarct remodelingand function by testing the serial hypotheses that: a) inadequate up-regulation of requisitereprogramming genes limits cell transdifferentiation efficiency, which can be optimized beyondcurrent thresholds via the comprehensive application of genomic activation strategies, b) thatthe density of (contractile) iCMs in infarct zones as well as indirect or paracrine (i.e., antifibrotic)mechanisms play critical roles in GMT/VEGF mediated infarct remodeling, and c) thatcardiac fibroblasts can be made susceptible to reprogramming in a clinically relevant fashion. The labemployscutting-edge molecular strategies and pre-clinical animal models to executethese aims. Congestive heart failure typically occurring as a result of myocardial infarction remains theleading cause of mortality from heart disease. Cardiac stem cell therapy has offered promise inanimal and clinical studies, but remains inherently constrained by the logistical challenges ofdelivering and integrating exogenous cells into a host myocardium. The recent discovery thatinduced cardiomyocytes (iCMs) could be generated directly from somatic cells offers theexciting possibility of bypassing stem cell staging and, perhaps more importantly, convertingscar fibroblasts in situ into iCMs, obviating entirely the challenges of cell implantation into … Continue reading →

Highlights of Cardio 2018 Conference Series LLC Ltd is esteemed to invite you to join the26th International Conference & Exhibition on Cardiology and Cardiovascular Medicinewhich will be held from November 12-13, 2018 Sydney, Australia which includes prompt Keynote Presentations, Oral Talks, Poster Presentations AndExhibitions. Summary:Cardio2018(Conference) Is To Meet Top & Best Cardiologists, Doctors,CardiologyExperts, Cardiac Surgeons, Vascular Medicine Specialists, Physicians, Health Care Professionals AtCardiology, Atherosclerosis, ClinicalCardiologyArrhythmia, Cardiac Surgery,Echocardiography, Cardiovascular Medicine, Arrhythmia, Cardiac Surgery Conferences, Events, Annual Meetings , Program From Clinics, Hospitals From Asia, Americas, Europe, USA, Middle East.Cardio 2018has been designed in an interdisciplinary manner with a multitude of tracks to choose from every segment and provides you with a unique opportunity to meet up with peers from bothindustryandacademiaand establish a scientific network between them. We cordially invite all concerned people to come join us at our event and make it successful by your participation. A comprehensive range of topics will be discussed in the event including maternalClinical Cardiology, Cardiac Pharmacology, Cardiac Regeneration & Remodeling, Heart Stroke,Cardio Metabolic Health,Cardio-Oncology, Cardiovascular Epidemiology,Cardiovascular Nursing, Cardiovascular Radiology And Intervention, Cardiac Imaging & Anesthesia, Critical Care Cardiology,Heart FailureAndCardiomyopathies, Pediatric Cardiology,Cardiac Arrhythmia, Cardiac Diseases, Cardiac Surgery. It is our ideology to bring maximum exposure to … Continue reading →

1.Sugimoto K, Hui SP, Sheng DZ, Kikuchi K. Dissection of zebrafish shha function using site-specific targeting with a Cre-dependent genetic switch.eLIFE DOI: 10.7554/eLife.24635. 2. Sugimoto K, Hui SP, Sheng DZ, Gonzalez-Rajal A, Nakayama M, Kikuchi K. Zebrafish Foxp3a is required for the maintenance of immune tolerance.Developmental and Comparative Immunology 73:156-62 (2017). 3. Xiang M. S. W., Kikuchi K, Endogenous mechanisms of cardiac regeneration.International Review of Cell and Molecular Biology 326:67-131 (2016). 4.Karra K, Knecht A, Kikuchi K, Poss KD. Myocardial NF-B activation is essential for zebrafish heart regeneration.Proceedings of the National Academy of Sciences of USA 112:13255-13260 (2015). 5.Kikuchi K. Dedifferentiation, transdifferentiation, and proliferation: mechanisms underlying cardiac regeneration in zebrafish.Current Pathobiology Reports 3:81-88 (2015). 6.Kikuchi K. Advances in understanding the mechanism of zebrafish heart regeneration.Stem Cell Research 13:542-555 (2014). 7. Nachtrab G, Kikuchi K, Tornini VA, and Poss KD. Transcriptional components of anteroposterior positional information during zebrafish fin regeneration.Development. 140:3754-64 (2013) 8.Fang Y, Gupta V, Karra R, Holdway JE, Kikuchi K, Poss KD. Translational profiling of cardiomyocytes identifies an early Jak1/Stat3 injury response required for zebrafish heart regeneration.Proceedings of the National Academy of Sciences of USA 110:13416-21 (2013). 9. Guner-Ataman B, Paffett-Lugassy N, Adams MS, Nevis KR, Jahangiri L, Obregon … Continue reading →

Introduction In 2009 cardiovascular disease (CVD) still accounted for 32.3% of all deaths in the United States and therefore continues to be one of the main causes of death (1). From 1999 to 2009, the rate of death due to CVD has declined, but nevertheless the burden of disease remains high. Although improved medical care and acute management of myocardial infarction have led to a considerable reduction of early mortality rate survivors are susceptible to an increased prevalence of chronic heart failure as they develop scarring followed by ventricular remodeling despite optimum medical care (2,3). Interestingly, cardiovascular operations and interventional procedures increased by 28% from 2000 to 2010 implicating an enormous cost factor for the healthcare system (1). For 2009, it was estimated that the direct and indirect costs of CVD and stroke add up to about $312.6 billion in the United States, which was more than for any other diagnostic group (1). The main issue of current pharmacological, interventional or operative therapies is their disability to compensate the irreversible loss of functional cardiomyocytes (4). Hence, the future challenge of cardiovascular therapies will be the functional regeneration of myocardial contractility by novel concepts, like cell based therapy, tissue engineering or … Continue reading →

Results from a ground-breaking Smidt Heart Institute clinical trial show that an infusion of cardiac stem cells helps damaged hearts regrow healthy muscle. The first-in-man clinical trial, based on technologies and discoveries made by Eduardo Marbn, MD, PhD, and led by Raj Makkar, MD, explored the safety of harvesting, growing and giving patients their own cardiac stem cells to repair heart tissue injured by heart attack. The study's findings, published in The Lancet, show that heart attack patients who received stem cell treatment demonstrated a significant reduction in the size of the scar left on the heart muscle; this is a pioneering stem cell result, says Marban, who notes the study shows actual regeneration of tissues. With support from the California Institute for Regenerative Medicine, the Heart Institute team is now planning future clinical trials to treat advanced heart disease patients with stem cells. The process to grow cardiac-derived stem cells involved in the study was developed earlier by Marbn when he was on the faculty of Johns Hopkins University. The university has filed for a patent on that intellectual property, and has licensed it to a company in which Marbn has a financial interest. No funds from that company … Continue reading →

1 Department of Health Sciences, University of Jan, Campus Las Lagunillas, S/N, Jan 23071, Spain 2 Research Unit, University Hospital "Virgen de las Nieves", Avda. de las Fuerzas Armadas, 2, Granada 18014, Spain 3 Biopathology and Regenerative Medicine Institute (IBIMER), University of Granada, Avda. del Conocimiento S/N. CP Armilla, Granada 18100, Spain 4 Department of Human Anatomy and Embryology, University of Granada, Avda. De Madrid, 11, Granada 18012, Spain * Author to whom correspondence should be addressed. Received: 6 January 2013 / Revised: 20 March 2013 / Accepted: 20 March 2013 / Published: 28 March 2013 No MDPI and ACS Style Pern, M.; Garca, M.A.; Lopez-Ruiz, E.; Jimnez, G.; Marchal, J.A.How Can Nanotechnology Help to Repair the Body? Advances in Cardiac, Skin, Bone, Cartilage and Nerve Tissue Regeneration. Materials 2013, 6, 1333-1359. Pern M, Garca MA, Lopez-Ruiz E, Jimnez G, Marchal JA. How Can Nanotechnology Help to Repair the Body? Advances in Cardiac, Skin, Bone, Cartilage and Nerve Tissue Regeneration. Materials. 2013; 6(4):1333-1359. Pern, Macarena; Garca, Mara A.; Lopez-Ruiz, Elena; Jimnez, Gema; Marchal, Juan A.2013. "How Can Nanotechnology Help to Repair the Body? Advances in Cardiac, Skin, Bone, Cartilage and Nerve Tissue Regeneration." Materials 6, no. 4: 1333-1359. Show more … Continue reading →

Reparative stem cells have the capability to restore function to damaged tissue by renewing cell growth (shown in green) in cardiac cells destroyed by heart disease. Approximately 28 million Americans have been diagnosed with heart disease. Traditional medical therapies are not able to fully address the burden of disease, and the shortage of organs for transplantation remains a key barrier more than 117,000 people are on the national transplant list. This unmet need drives Mayo Clinic researchers to make new discoveries to accelerate regenerative solutions into clinical trials and rapidly provide new hope to patients who can't currently be treated. Cardiac regeneration is a broad effort that aims to repair irreversibly damaged heart tissue with cutting-edge science, including stem cell and cell-free therapy. Reparative tools have been engineered to restore damaged heart tissue and function using the body's natural ability to regenerate. Working together, patients and providers are finding regenerative solutions that restore, renew and recycle patients' own reparative capacity. Through the vision and generous support of Russ and Kathy Van Cleve, strong efforts are underway to develop discoveries that will have a global impact on ischemic heart disease. Mayo Clinic researchers are leading efforts in translating new knowledge into … Continue reading →

Reparative stem cells have the capability to restore function to damaged tissue by renewing cell growth (shown in green) in cardiac cells destroyed by heart disease. Approximately 28 million Americans have been diagnosed with heart disease. Traditional medical therapies are not able to fully address the burden of disease, and the shortage of organs for transplantation remains a key barrier more than 117,000 people are on the national transplant list. This unmet need drives Mayo Clinic researchers to make new discoveries to accelerate regenerative solutions into clinical trials and rapidly provide new hope to patients who can't currently be treated. Cardiac regeneration is a broad effort that aims to repair irreversibly damaged heart tissue with cutting-edge science, including stem cell and cell-free therapy. Reparative tools have been engineered to restore damaged heart tissue and function using the body's natural ability to regenerate. Working together, patients and providers are finding regenerative solutions that restore, renew and recycle patients' own reparative capacity. Through the vision and generous support of Russ and Kathy Van Cleve, strong efforts are underway to develop discoveries that will have a global impact on ischemic heart disease. Mayo Clinic researchers are leading efforts in translating new knowledge into … Continue reading →